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Abstract: Endoplasmic reticulum (ER) stress is an intriguing target with significant clinical importance
in chemotherapy. Interference with ER functions can lead to the accumulation of unfolded proteins,
as detected by transmembrane sensors that instigate the unfolded protein response (UPR). Therefore,
controlling induced UPR via ER stress with natural compounds could be a novel therapeutic strategy
for the management of prostate cancer. Tannic acid (a naturally occurring polyphenol) was used
to examine the ER stress mediated UPR pathway in prostate cancer cells. Tannic acid treatment
inhibited the growth, clonogenic, invasive, and migratory potential of prostate cancer cells. Tannic
acid demonstrated activation of ER stress response (Protein kinase R-like endoplasmic reticulum
kinase (PERK) and inositol requiring enzyme 1 (IRE1)) and altered its regulatory proteins (ATF4, Bip,
and PDI) expression. Tannic acid treatment affirmed upregulation of apoptosis-associated markers
(Bak, Bim, cleaved caspase 3, and cleaved PARP), while downregulation of pro-survival proteins
(Bcl-2 and Bcl-xL). Tannic acid exhibited elevated G1 population, due to increase in p18INK4C and
p21WAF1/CIP1 expression, while cyclin D1 expression was inhibited. Reduction of MMP2 and MMP9,
and reinstated E-cadherin signifies the anti-metastatic potential of this compound. Altogether, these
results demonstrate that tannic acid can promote apoptosis via the ER stress mediated UPR pathway,
indicating a potential candidate for cancer treatment.
Keywords: ER stress; molecularly targeted therapeutics; tannic acid; apoptosis; unfolded protein response
1. Introduction
Prostate cancer is the second leading cause of cancer related death in men in the United States [1].
According to Cancer Statistics, in 2018, it accounts for 19% of cancer incidences in men among all of
the cancers in the United States [1]. It is estimated that there will be 164,690 new cases of prostate
cancer diagnosed in 2018 with conservative projections of 29,430 deaths due to this disease. Current
clinical treatment consists of both single and combination chemotherapy along with radiation and
surgical procedures. Clinically, polychemotherapy offers a better survival advantage when compared
to other therapies. However, empirically designed drugs in combination may not be effective due to
distinctly different mechanisms of action, pharmacokinetics, and pharmacodynamic profiles of the
individual drugs. In general, combination drug regimens have a smaller therapeutic window, making
the patient’s individual response to therapy an important consideration when navigating drug therapy
options [2,3]. Additionally, such drug combination treatment results in severe systemic toxicity.
Endoplasmic reticulum (ER) is a crucial organelle that is responsible for several fundamental cellular
activities, including synthesis, folding, maturation, and translocation of intracellular proteins. The ER serves
as the principal site for synthesis and the folding of proteins in cells [4]. ER stress leads to accumulation
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of unfolded or misfolded proteins that are removed by proteolytic mechanisms. Often, these proteins
follow ubiquitin/proteasome and autophagy/lysosomal mediated degradation [5]. Disturbances to ER
homeostasis i.e., accumulation of unfolded/aggregated proteins promote an ER adaptation capacity, which is
known as unfolded protein response (UPR). Such UPR activation has been implicated in several metastasic
cancers [6]. The UPR phenomenon is mainly a pro-survival process but prolonged and severe ER stress
results in significant protein accumulation and will induce a UPR that will lead to cell death. The mechanisms
regulating the cell’s survival/death decision under ER stress might be crucial in order to target tumor cells
and overcome tumor resistance during therapies [7]. Protein kinase R-like endoplasmic reticulum kinase
(PERK), activating transcription factor 6 (ATF6), and inositol requiring enzyme 1 alpha (IRE1α) are three
branches in the ER lumen that are considered to be ER stress sensor proteins [7]. Binding immunoglobulin
protein (BiP) (also known as 78 kDa glucose-regulated protein, GRP-78) is a master regulator of ER function
and a key molecule responsible for inducing UPR and cancer cell survival [8]. The up-regulated expression
of Bip is known to cause activation of ER stress. Chronic ER stress activates UPR in the ER lumen leading
to severe stress in cells which often induces apoptosis in cancer cells [7]. Thapsigargin is a potent and
specific cell-permeable inhibitor of the ER Ca2+-ATPase [9]. Thapsigargin treatment resulted in reduced ER
calcium levels that offer lowered chaperone activity. This promotes the accumulation of unfolded proteins
in ER lumen. Thus, thapsigargin is considered as a positive ER stress inducer (like tunicamycin, Brefedin A,
dithiothreitol, and MG132) which activates the UPR [9]. Further, prolonged or severe ER stress triggers cell
death by cross-talk with the intrinsic or extrinsic apoptotic pathways [10]. If a small molecule stimulates ER
stress, it may not only induce cancer cell apoptotic mechanisms but also inhibit the tumor growth, migration,
and invasion. Epithelial to Mesenchymal Transition (EMT) is the primordial event in the cancer progression
and metastasis; in which tumorigenic cells transform in mesenchymal phenotypes [11]. Therefore, in the
therapeutic perspective, the induction of ER stress could be an attractive molecular target in cancer therapies.
Dietary compounds, such as phenolics and flavonoids, have been validated to display anti-cancer
activity and reduced the risk of prostate cancer [12–14]. Also, curcumin, quercetin, rutin, morin, resveratrol,
gallic acid, (phenolics of natural origin), and so on were demonstrated to inhibit proliferation of prostate
cancer cells [15,16]. Other phenolic and flavonoid compounds, such as ellagic acid and apigenin, have
been demonstrated to inhibit and prevent cancer and its recurrence of various malignancies [17,18].
Tannic acid (TA) is a naturally occurring polyphenolic compound that is widely found in plant
seeds/leaves, fruit skins, and wood bark. Studies suggest that this molecule exhibits chemopreventive,
chemosensitization, and antitumor properties [19]. Tannic Acid is commonly used as a food, drink,
and pharmaceutical additive. More importantly, TA is recognized as a safe compound by the US Food
and Drug Administration (See 9 CFR 318.7, FDA food additive list) [20]. Thus, tannic acid is commonly
used in beer clarification, soft drinks and juices, especially to enhance taste and color stabilization in
wine [21]. Tannic acid is a hydrolysable phenolic molecule, containing a central glucose unit and gallic
acid esterified to it. The hydroxyl and carboxyl functional groups in TA allows for binding proteins and
DNA, making TA an important candidate for antimicrobial and antifungal agents [22,23]. Chemopreventive
and chemosensitization activity of TA has been demonstrated against several human carcinomas such
as breast, ovarian and skin cancers [24–27]. Literature suggests that TA can inhibit various oncogenic
signaling cascades [28,29]. However, TA’s influence on induced ER stress mediated UPR signaling has
never been investigated. Thus, in this study, we aim to elucidate these effects of TA for its ability to reduce
risk in prostate cancer cells. The results of this study demonstrate that TA inhibited proliferation, invasion,
and migration of human advanced prostate cancer cells via inducing ER stress modulation.
2. Results
2.1. Tannic Acid Treatment Suppresses Proliferation and Clonogelnicity of Prostate Cancer Cells
Tannic acid acts as a chemopreventing and anti-cancer agent in various cancers. Herein, we tested
its cytotoxicity against prostate cancer cells. The cytotoxic effects of serial concentrations of TA (for
48 and 72 h treatment) on prostate cancer cells were examined using the MTS assay (Figure 1A).
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Notably, TA treatment caused a dose dependent (1.25–40 µM) decrease in viability of C4-2, DU 145 and
PC-3 cells. The IC50 (the concentration of TA where the cells growth is reduced by half) in all prostate
cancer cells was achieved within a concentration range of 20–25 µM for 48 h and 9–13 µM for 72 h
treatment. In detail, IC50 values were calculated as: 20.80 ± 1.50, 24.52 ± 1.95, and 23.61 ± 1.74 µM
(48 h treatment), and 12.92 ± 1.18, 8.95 ± 0.80, 8.53 ± 0.80 (72 h treatment) in C4-2, DU 145, and PC-3
cells, respectively. However, we did not observe any significant effect of TA on PWR-1E normal
prostate epithelial cells. Next, the effect of TA treatment was examined on colony inhibition of prostate
cancer cells (Figure 1B,C). Although a colony formation assay is time-consuming, it is considered the
gold standard of in vitro assays for testing the activity of compounds and to test long term growth
of cell lines [30]. TA treatment inhibited formation of colonies in a (2.5–10 µM) dose-dependent
manner. These results demonstrate that TA efficiently inhibited the growth and clonogenicity of
prostate cancer cells. TA effects are very similar in all three prostate cancer cell lines (C4-2, DU 145,
and PC-3) tested. Furthermore, PC-3 and DU 145 cell lines exhibits similar phenotypic characteristics.
Therefore, we have chosen C4-2 and PC-3 cell lines for further functional studies, such as gene and
protein profiling studies.
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Figure 1. Tannic acid inhibited the growth of prostate cancer cells. (A) Effect of Tannic acid (TA) on
cell proliferation of human prostatic epithelial cells (PWR1E) and prostate cancer (C4-2, DU 145 and
PC-3) cells. Cells (5000) were seeded in each well of 96-well plate and allowed to grow overnight,
the cells were then treated with the described concentrations for 48 and 72 h. The line graphs represent
the percent proliferation compared with the vehicle-treated group cells. Data indicated TA is not
toxic to PWR1E cells; (B) Effect of TA on clonogenic potential of prostate cancer cells. Representative
colony images f contr l and TA treated C4-2, DU 145, and PC-3 cells; and, (C) Bar gra hs indicating
quantification of colony formation in C4-2, DU 145 and PC-3. Data represent the mean of triplicates
± SEM, ** p < 0.01, and *** p < 0.001.
2.2. Tannic Acid Treatment Upregulates the Expression of ER Stress Regulatory Proteins
The ER stress pathway is considered a novel pathway of interest in regards to the development of
cancer therapeutic agents [7]. Since TA inhibited proliferation of prostate cancer cells, we examined
the involvement of TA in ER stress pathway in prostate cancer cells. To test the ER associated
Cancers 2018, 10, 68 4 of 17
stress pathway, we examined the activation of ER stress marker sensors and their downstream
signaling molecules.
Tannic acid treatment (24 h) resulted in the dose dependent expression of Bip protein in prostate
cancer cells as compared to the control, as determined by Western blot analysis (Figure 2A). Tannic
acid treatment efficiently induced the expression of these sensor proteins (PERK and IRE1α) as
compared to the control group (Figure 2A). The activation of the PERK protein by TA treatment
prompted us to examine the downstream UPR target proteins, activating transcription factor 4 (ATF4)
and transcription factor C/EBP, homologous protein (CHOP). Interestingly, both ATF4 and CHOP
proteins were significantly elevated with TA treatment. In addition, TA is very effective in inducing
these protein expressions at the mRNA levels (Figure 2B) (primers used for this experiment was
shown in Table 1). These results found elevated the expressions of PERK (2.13 ± 0.33, 2.11 ± 0.67,
1.56 ± 0.28 and 4.62 ± 0.14, 4.49 ± 0.80, 4.72 ± 0.18 fold), Bip (2.25 ± 0.05, 2.54 ± 0.07, 2.61 ± 0.14 and
3.68 ± 0.14, 3.91 ± 0.48, 4.67 ± 0.73 fold), ATF4 (2.56 ± 0.10, 2.29 ± 0.17, 1.94 ± 0.82 and 3.89 ± 0.06,
4.22 ± 0.29, 3.94 ± 0.28 fold), CHOP (1.81 ± 0.20, 1.83 ± 0.20, 2.08 ± 0.27 and 3.40 ± 0.31, 3.63 ± 0.46,
and 4.22 ± 0.62 fold), and eukaryotic translation initiation factor 1 (EIF2S1) (1.73 ± 0.08, 1.98 ± 0.35,
1.49 ± 0.38, and 4.07 ± 0.43, 3.97 ± 0.77, and 2.59 ± 0.27 fold), during TA 10 and 20 µM treatments
with respect to control in C4-2, DU 145, and PC-3, respectively.
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in TA treated cells for PERK, eukaryotic translation initiation factor 1 (EIF2S1), binding 
immunoglobulin protein (BiP), transcription factor C/EBP, homologous protein (CHOP), and ATF4 
determined by qRT-PCR analysis. GAPDH was used as an internal control. Data represent the mean 
Figure 2. Tannic acid induced ER stress in prostate cancer cells. (A) Western blot analysis of Protein
kinase R-like endoplasmic reticulum kinase (PERK), inositol requiring enzyme 1 alpha (IRE1α),
and activating transcription factor 4 (ATF4) signaling in prostate cancer cells after dose-dependent
treatment ith T . Briefly, cells were treated with indicated concentrations of TA, protein extracts were
prepared and subjected for western blot analysis to detect the protein levels. β-Actin antibody served
as an inter al co trol; (B) Gene expression studies endoplasmic reticulum (ER) stress markers in TA
treated cells for PERK, eukaryotic translation initiation factor 1 (EIF2S1), binding immunoglobulin
protein (BiP), transcription factor C/EBP, homologous protein (CHOP), and ATF4 determined by
qRT-PCR analysis. GAPDH was used as an internal control. Data rep esent the mean of triplicates
± SEM, ** p < 0.01; (C) Cells were grown and exposed to TA and Thapsigargin. Western blot analysis
of regulatory protein expression of ER stress in TA and thapsigargin (TG) treated C4-2 and PC-3 cells.
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To confirm the effectiveness and validate the central role of TA (20 µM) as an ER stress inducer,
we further quantified the expression of PERK, IRE1α, and CHOP at the protein through Western blot
and compared that data with thapsigargin (2 µM, a positive reference control) (Figure 2C). Tannic acid
is very effective in inducing these proteins indicating their roles in inducing ER stress. Additionally,
these results were further evaluated at mRNA level through q-PCR (Figure S1).
2.3. TA Treatment Effectively Arrests the Cell Cycle and Modulates Cell Cycle Regulatory Proteins
Previous studies have demonstrated that ER stress triggers G1-phase cell cycle arrest in various
cancer cells [31]. Various polyphenols showed cytostatic effects on prostate cancer cells [32]. Therefore,
we investigated the cell cycle analysis using PI/RNase staining solution, employing flow cytometry.
Tannic acid treatment (5 and 10 µM) after 24 h demonstrated an increase in the G1 population of
prostate cancer cells (Figure 3A) as compared to the untreated control cells. The percentage of G1 phase
increased: from 48.78% (C4-2 control cells) to 65.57% and 74.18%; 55.89% (DU 145 control cells) to
62.86% and 76.30%; 42.98% (PC-3 control cells) to 60.90% and 77.64%; after treatment with 5 and 10 µM
TA, respectively. In addition, 20 µM TA treatment induced a prominent rise in apoptotic populations,
as observed (Figure 3A). To further investigate the molecular mechanism underlying cell cycle arrest,
we examined the effect of TA treatment on cell cycle regulatory proteins (cell cycle inhibitory proteins
(p21INK4C and p18INK4C) and cyclin D1) in prostate cancer cells. Western blot analysis demonstrated
that TA treatment significantly increased the protein levels of p21WAF1/CIP1 and p18INK4C, while it
decreased the protein levels of cyclin D1 (G1 phase positive regulator) in prostate cancer cells when
compared to control cells (Figure 3B).
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Figure 3. Tannic acid in uces G1 phase arrest and apoptosis in prostate cancer cells. r st te c cer cells
were treated with TA for 24 h and cell cycle analysis was performed by flow cytometer. (A) Histogram
plot of C4-2, DU 145 and PC-3 cells after treatment of 5, 10, and 20 µM TA. Untreated cells were used
as control; (B) Directive role of TA on cell cycle regulatory proteins and its effect on G1 phase arrest.
Western blot analysis of G1 phase cell cycle regulatory proteins in prostate cancer cells treated with
TA. Tannic acid treated cell lysates were prepared and subjected for Western blot analysis. β-actin was
probed for equal protein loading in each lane; and, (C) Cells treated with TA 10 and 20 µM for 24 h,
cell lysates were collected and immunoblotted for apoptotic protein expressions.
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2.4. Tannic Acid Treatment Induced Apoptosis via ER Stress Mediated Signaling
To investigate the mechanistic role of TA in apoptosis, we sought to examine the expression of key
proteins that are associated in cell proliferation and the survival process. This data suggests a dose-dependent
decrease in the expression of anti-apoptotic proteins (Bcl-xL and Bcl-2), while a simultaneous increase in the
expression of pro-apoptotic proteins (Bim and Bak) with 24 h TA treatment. It is known that the activation
of PERK and IRE1α correlates with those of decreased expression of Bcl-2 and Bcl-xL. Cleaved caspase-3
and cleaved PARP appearance further supports the apoptosis role of TA (Figure 3C).
2.5. Tannic Acid Treatment Inhibited Migratory and Invasive Potentials of Prostate Cancer Cells
We determined the effects of TA on migration (wound healing i.e., scratch assay and Boyden
chamber assay) and invasion (matrigel invasion) assays in prostate cancer cells. Upon treatment,
the wound closure of the scratch was measured as reported previously [33]. In this assay, initial size of
wound values were normalized to 100% in all C4-2, DU 145, and PC-3 cells. After 48 h, the wound
size closure in control cells were found to be 93 ± 1.2%, 92 ± 1.85%, and 90 ± 1.45% (C4-2, DU 145,
and PC-3) while 25 ± 0.88%, 34 ± 1.73%, and 34 ± 2.64% (10 µM of TA) and 5 ± 1.21%, 11 ± 1.45%,
and 11 ± 0.89% (20 µM of TA) in C4-2, DU 145, and PC-3 cells, respectively (Figure 4A,B).
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Figure 4. Tannic acid inhibited migratory and invasive attributes of prostate cancer cells. (A) Wound
healing assay. In cell migration assay, a uniform scratch was made in 80% confluent monolayer cultures
of prostate cancer cells and the extent of closure was monitored in presence of TA (10 and 20 µM) under
phase-contrast microscopy and imaged at 0 and 48 h at 20×magnification; (B) Percent wound closure
with TA treatment in C4-2, DU 145 and PC-3 cells; (C) Boyden chamber assays of TA treated prostate
cancer cells. Cells were imaged under phase-contrast microscopy at 20× magnification; (D) Bar graph
displaying relative cell number of migrated cells (per unit area) in TA-treated groups; (E) Matrigel
Invasion assays of TA treated prostate cancer cells; and, (F) Bar graph displaying relative cell number
of cells invaded (per unit area) in TA-treated groups. Data represent the mean of triplicates ± SEM,
** p < 0.01 and *** p < 0.001.
Similarly, the anti-migratory potential of TA against C4-2, DU 145, and PC-3 cells was ratified
through Boyden chamber studies. The graphical representation of base cell numbers of C4-2, DU 145,
and PC-3 cells after TA treatment during migration and invasion studies were shown in Figure S2.
This assay demonstrated a significant decreased 52.33 ± 2.33%, 39 ± 2.64%, and 36 ± 2.24% (C4-2,
DU 145, and PC-3) migration of cells with 10 µM TA treatment while 20 µM TA treatment resulted in
almost negligible migration, 18.33 ± 2.02%, 12.33 ± 2.6%, and 14.66 ± 1.76% (C4-2, DU 145, and PC-3)
(Figure 4C,D). Overall, these results confirm that TA has effective anti-migratory ability.
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To examine the effect of TA on the invasive capability of prostate cancer cells, a matrigel invasion
assay was employed. It was clear that after the cells were treated with TA, the invasive potential of
the cells drastically diminished in comparison to the untreated cells (Figure 4E). The relative number
of invaded cells was measured and graphically represented (Figure 4F). These data indicate that
the relative number of invaded cells was reduced to less than half of its number, 38.66 ± 1.45%,
27.67 ± 1.76%, and 36 ± 2.64% even with 10 µM TA treatment in C4-2, DU 145, and PC-3 cells when
compared with non-treated controls. Furthermore, this effect is much more significant with 20 µM
treatment at 24 h (17 ± 1.52%, 6.66 ± 0.88%, and 14.66 ± 1.76%). Altogether, the TA annihilated the
invasive attributes of prostate cancer cells.
To further validate TA’s role in inhibiting migration and invasion, we assessed the expression
profiles of the epithelial marker (E-cadherin) and mesenchymal markers (MMP2 and MMP9) of
EMT [34] through immuno-blot studies. Tannic acid increased the expression of E-cadherin (cell-cell
adherent membrane junction protein) in both C4-2 and PC-3 cells, whereas MMP2 and MMP9 proteins
were inhibited in a dose-dependent manner at 24 h (Figure 5A) as compared to control cells. These
results were further confirmed by qPCR analysis (Figure 5B). Tannic acid treatment (20 µM) effectively
re-expressed the E-cadherin expression 9.32 ± 0.79, 7.65 ± 0.84 and 8.37 ± 1.38 fold in C4-2, DU 145,
and PC-3 cells, respectively (Figure 5B). In contrast, TA treatment of 20 µM inhibited the expression of
MMP2 and MMP9, the key downstream proteins that drive the EMT in prostate cancer [35]. The fold
change of MMP2 was found to be 0.27 ± 0.05, 0.24 ± 04, and 0.47 ± 0. 05, while the MMP9 fold change
was found to be 0.37 ± 0. 01, 0.64 ± 0. 02, and 0.32 ± 0. 04 in C4-2, DU 145, and PC-3 cells, respectively.
These data indicate an apparent influence in the mRNA levels of main effectors of the EMT signaling
pathway in response to TA.
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Figure 5. Tannic acid altered the EMT regulatory protein markers in prostate cancer cells. (A) estern
analysis of Epithelial to Mesenchymal Transition (EMT) markers in TA treated cells. Values shown
above the blots are the densitometry analysis of each protein band normalized with respective β-actin
value; ( ) e e ex ressio st dies of EMT markers, such as E-Cadherin, MP2 and MMP9 in
TA-treated cells. Data represent the mean of triplicates ± SEM, ** p < 0.01.
In addition, we validated the above results of expression profiles of proteins through microarray analyses
(Figure 6, Table S1) which is consistent with real time and western blot studies (Figures 2–5). The heat
maps were generated using heatmapper software (University of Alberta, Edmonton, AB, Canada) [36].
These results reflected that activation of the ER stress (PERK and IRE1α) signaling pathway could directly or
indirectly contribute to TA-induced cell apoptosis (Figure 6B).
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3. Discussion
Prostate cancer is a slo -progressing disease that requires long ter care. Additionally, it is
highly challenging to manage and treat with conventional regimens due to systemic toxicity, distant
etastasis, and drug resistance. The outcomes and patient compliance have not improved significantly
over the last few decades [37]. The quest to develop a highly specific, efficient, and safe molecule for
treatment of cancers is highly desirable. Like many polyphe ols (nutraceuticals), TA is commonly
consumed in the form of food additives r as an excipient in many commercial drinks [38]. In a dition,
the FDA i entified TA as a safe molecule. Tannic acid exhibited chemopreventive and anti-prolif rative
char cteristics in a broad range of ca cers by targeting multiple oncogenic signaling pathways to
suppress their proliferation activity [28,29]. Als , gallic acid, a metabolite of tannic acid, was found
to be ineffective towards normal epitheli l cells of prostat nd was consist nt with our current
findings [39]. However, the mechanism underlying ER stress mediated apoptotic de th actions was
not reported. For the first time, the present study revealed that tannic acid is proficient in inhibiting
the growth of human prostate cancer cells due to its cytotoxic, cytostatic, and ER stress induction
(Figures 1–3). In addition, this study demonstrated the apoptotic role of TA, as well as the inhibitory
effect it has on both migration and invasion f prostate ca cer cells (Figures 4 and 5).
The e oplasmic reticulum (ER) is an intricate organelle that is vital for cellular function and
survival. When ER activity is hindered, the accumulation of unfolded proteins stimulates the
transmembra e sensors to initiate the UPR ultimately restoring ER homeostasis [40]. When the
UPR fails to restore ER h meostasis and attenuates ER stress, the UPR activation induces apoptosis.
Thus, measuring ER stress-mediated apoptosis will aid us [41] in developi g new therapeutic options
for cancer treatment. Plant based polyphenols have been reported to induce apoptosis and cell
cycle arrest via induction of the ER stress mediated UPR in cancer cells. PERK and IRE1α are
transmembrane proteins that are located in the ER lumen and are proximal trans ucers of the
mammalian UPR pathway [42,43]. Initiation of stress leads to promoter activation of the ER
stress response element found in the promoters of various UPR targets including the transcription
factor CHOP, and ER chaperones like Bip [44,45]. Comparably, the induction of Bip and consistent rise
in CHOP expression was observed in all prostate cancer cells during dose-dependent treatments of TA,
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which was further affirmed from potential studies at both gene and protein levels (Figure 2A,B). Also,
activated PERK phosphorylates eIF-2α, leading to an immediate, as well as transient, protein synthesis
inhibition [46]. The gene expression levels of eIF-2α (EIF2S1) was decreased during drug treatments,
thus strengthening the rationale of TA-mediated ER stress by activation of PERK. These results manifest
that TA induces ER stress-mediated UPR in prostate cancer cells.
Earlier studies suggest that during ER stress ATF4, a transcriptional regulator, translocates to
the nucleus thereby inducing the expression of ER chaperones, such as protein disulfide isomerase
(PDI) and various genes that are involving both antioxidant response genes and genes responsible
for cellular functions like autophagy [47]. Also, PDI is an ER chaperone that is recruited during
ER stress and is responsible for the formation of disulfide bonds in proteins [48]. Paradoxically,
protein synthesis inhibition will induce ATF4 at the translational level, leading to activation of its
downstream targets [49,50]. Comparatively, we demonstrated that the expression of PDI and ATF4
was decreased and elevated, respectively, during drug and TG treatments. We also affirmed the rise of
CHOP expression, and the downstream of ATF4 during TA and TG (positive reference for ER stress)
treatments at both the gene and protein levels through potential (Western) and qPCR studies (Figure 2C
and Figure S1). Overexpression of BiP diminishes the CHOP induction in ER stress and reduces ER
stress-induced apoptosis [51]. Research insights revealed that CHOP is implicated in programmed cell
death in response to impaired ER function [52]. Therefore, the rise of CHOP during TA treatments
mediates ER stress-induced apoptosis.
Mechanistic studies have shown that the overexpression/microinjection of CHOP protein into
cells resulted in G1/S cycle arrest and/or apoptosis [53,54]. Earlier reports suggest that natural
compounds of phenolic origin arrest the G1 phase through the ER stress pathway in lung cancer [31,55].
The decrease of eIF-2α gene expression levels causes the cessation of cyclin D1 protein synthesis,
which explains the basis of G1 phase arrest seen in prostate cancer cells during TA treatments.
Interestingly, the present study also shows that TA treatment arrests cell cycle phase distribution
in association with the decreased expression of cyclin D1 and increased expression of p18INK4C and
p21WAF1/CIP1 proteins (Figure 3B). This indicates that the TA induced G1 arrest might be mediated
through the up-regulation of p21WAF1/CIP1 protein, which enhances the formation of heterotrimeric
complexes with G1-S Cdks and cyclins, thereby inhibiting its activity [56]. Our data also revealed
that TA treatment reduced the protein level of Bcl-2, which might be associated with cell cycle arrest
and apoptosis in prostate cancer cells, which is consistent with previous reports [57]. Gallic acid,
which is a structurally similar phenolic acid, induced G1 phase arrest in human leukemia HL-60 cells
through inhibiting cyclin D1 pathway [58], which fortifies our results. Furthermore, these findings
are in accordance with earlier reports on the effect of tannic acid on breast cancer cells. Altogether,
these results confirmed that TA treatment not only induced cytotoxic effects in prostate cancer cells,
but also promotes the G1 cell cycle arrest via modulating key cell cycle regulatory proteins in prostate
cancer cells.
Apoptosis is considered to be the main protective mechanism against cancer initiation and
progression, otherwise cancer cells develop acquired resistance. On the other hand, the apoptotic
process is controlled by both intrinsic and extrinsic pathways. An intrinsic apoptotic pathway
(imbalance of pro-apoptotic and anti-apoptotic proteins) involves a caspase mediated cell death
through transforming pro-caspases into active caspases. ER stress induced apoptosis utilizes this
intrinsic pathway mechanism. The results indicate that TA potentiates such apoptosis machinery by
inducing pro-apoptotic proteins (e.g., Bak and Bim) as well as decreased expression of anti-apoptotic
proteins (Bcl-2 and Bcl-xL) (Figure 3C). Caspase-3 is known as executioner caspase, and after being
activated by the initiator caspases (caspase-8), it induces apoptosis and releases both caspase 3 and
PARP (cleaved caspase 3 and cleaved PARP) [59]. It is known that disruption of ER homeostasis
instigates the CHOP expression along with PERK activation leading to apoptosis. CHOP is the potent
regulator of apoptosis and decreases Bcl-2 protein expression [60]. We observed that TA induces the
expression of CHOP which in turn inhibited anti-apoptotic proteins of the Bcl-2 family (Bcl-2 and
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Bcl-xL) and triggers the pro-apoptotic protein expression (Bim and Bak). Such events changes cell
status from survival to apoptosis. More importantly, an induced expression of classical apoptotic
protein markers (cleaved caspase 3 and cleaved PARP) suggests that TA triggers cell death in prostate
cancer cells. CHOP is a transcriptional factor and is highly associated with growth arrest and apoptosis
under ER stress and following DNA damage [61]. These events suggest that TA-induced apoptosis is
mediated through an intrinsic mode of apoptotic signaling activation.
Tannic acid exhibits the polytrophic nature, therefore, it is possible to attenuate other cancer
related pathways. Our analyses have demonstrated that TA not only regulated cell survival pathways,
but is also involved in the cell cycle, cell invasion, and metastasis. Interestingly, our study has shown
that TA induced apoptotic cell death and decreased cell migration and invasion (Figure 4). In another
subset of experiments, we found that TA also inhibited EMT by inhibiting its key players in C4-2, DU
145, and PC-3 metastatic prostate cancer cells. We found the expression of some of the key players
in EMT, such as epithelial marker (E-cadherin), was restored while mesenchymal markers (MMP2
and MMP9) were deregulated during dose-dependent TA treatments (Figure 5). Further, scratch,
Boyden, and Matrigel invasion results supported and reaffirmed the anti-metastatic activity of TA and
its inhibition attributes towards EMT (Figure 4). Thus, these results altogether illustrate the molecular
activity of TA and its holistic mechanisms in inducing apoptosis in prostate cancer cells (Figure 6B).
Overall, this study suggests that TA is strongly correlated with ER stress and intrinsic apoptosis,
which were confirmed by the expression levels of proteins. Additionally, Western blot analysis,
qRT-PCR data confirm that TA regulates protein and mRNA expressions of PERK, CHOP, EIF2S1,
Bip, and ATF4, proteins. These results demonstrate that TA treatment may be involved in cell growth
inhibition via ER stress signaling Tannic acid might be a good candidate for combinational therapy and
a highly important molecule for reducing the occurrence of prostate cancer [62]. It is well understood
that ER stress can play a key role in autophagy regulation and oxidative stress. This aspect of ER stress
is not evaluated in this work. However, we would consider delineating such role and validation of TA
in our future studies.
4. Materials and Methods
4.1. Materials and Reagents
All reagents, solvents, chemicals, and cell culture plastics were purchased from Sigma–Aldrich
Co. (St. Louis, MO, USA) and Fisher Scientific (Pittsburgh, PA, USA), unless otherwise noted. All of
the chemicals and reagents were used as received without further purification. Prostate cancer
cell lines, C4-2, DU 145, and PC-3 were purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) and were cultured in Roswell Park Memorial Institute medium (RPMI-1640)
containing 10% (v/v) fetal bovine serum (FBS), and 1% (w/v) penicillin–streptomycin (Gibco, Thermo
Fisher Scientific, Grand Island, NY, USA) and incubated at 37 ◦C in a humidified 5% CO2—95%
air atmosphere (Thermo Fisher Scientific, Waltham, MA, USA). For most of the in vitro cell culture
experiments, cells were trypsinized when the confluence level was about 80% and above, seeded
in either 6 or 96-well plates, and were allowed to attach overnight to the plate before starting
any treatments.
4.2. Cell Proliferation Assay
Cell proliferation was determined using CellTiter 96® AQueous One Solution Cell Proliferation
Kit (MTS reagent, Promega Corporation, Madison, WI, USA) [63–66]. Briefly, 5 × 103 cells in 100 µL
culture medium were seeded into each well of a 96-well plate and allowed to attach overnight. Then,
cells were treated with 1.25–40 µM of TA for 48 and 72 h, respectively. After completion of the treatment
period, 20 µL MTS reagent was added to existing medium in the wells for 2–3 h. The intensity of
the absorbed color of intracellular formazan was measured at 490 nm using a microplate reader
(Cytation™ 5, BioTek Instruments, Winooski, VT, USA). The percentage of cell growth was calculated
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as the percentage of absorption of color intensity of the treated cells to the absorption of color intensity
of untreated cells.
4.3. Colony Formation Assay
The effects of TA on colony inhibition of prostate cancer cells were tested by colony formation
assay [65,67,68]. Briefly, cells were seeded at the density of 500 cells/well in 12-well plate and grown
for two days, at 37 ◦C in presence of 5% CO2. Then, cells were treated with 2.5, 5, and 10 µM TA
for seven days. On the 8th day, the medium was aspirated and replaced with fresh TA free medium
containing 10% FBS. Subsequently, cells were allowed to grow till 14 days. On day 15, the cells were
washed with 1X PBS and fixed using cold methanol for 1 h. After incubation, cells were washed under
slow running tap water for 1 min. Then, cells were stained using 1 mL of hemotoxylin (Thermo Fisher
Scientific, Waltham, MA, USA) in each well for 2 h, and then cells were further washed using tap
water. The plates were dried and imaged under UVP imager BioSpectrum® 500 Imaging System (UVP,
Upland, CA, USA) for visualization and documentation.
4.4. Cell Cycle Analysis
To study the effect of TA on the cell cycle, C4-2, DU 145, and PC-3 cells were treated with TA
for 24 h after seeding in 6-well plates. After treatment, cells were trypsinized, washed with 1X PBS,
and incubated in 70% ethanol; cells were kept at −20 ◦C overnight for fixation. The next day, cells were
centrifuged, washed, and incubated with Propidium iodide (PI) solution, FxCycle™ PI/RNase Staining
Solution (Thermo Fisher Scientific, Waltham, MA, USA) at 37 ◦C for 1 h [64,69,70]. The distribution of
cells in the different cell-cycle phases was analyzed from the DNA content histogram using Accuri C6
flow cytometer (Accuri Cytometers, Inc., Ann Arbor, MI, USA) in FL-2 channel.
4.5. Wound Healing Assay
Effect of TA on prostate cancer cell mobility was assessed using a scratch wound assay [71,72].
For this assay, prostate cancer cells (1 × 106) were cultured in a 6-well plate and after 80% confluency,
the cell layer was carefully wounded using a 200 µL sterile micropipette tip. Cancer cells were treated
with 10 and 20 µM TA, and the extent of drug effect was evaluated till 48 h, the residual gap length
was calculated from photomicrographs.
4.6. Cell Migration Assay
Effect of TA on prostate cancer cell migration was evaluated through a Boyden’s chamber assay
using Boyden chambers (8-µm; Corning, NY, USA) containing polycarbonate membrane [73]. Briefly,
upper chamber was added with 100 µL of 5 × 105 cells in serum-free medium and lower chamber
was added with 250 µL of 10% FBS medium. Cells were treated with TA (10 and 20µM) for 24 h
and migrated cells into lower chamber were fixed and stained with crystal violet for 30 min at
25 ◦C. The migrated cells were imaged under microscope (Eclipse Ti, Nikon, Melville, NY, USA)
at five random regions and the number of cells was counted to calculate the average number of
migrated cells per region (ImageJ program, NIH, National Institutes of Health: Bethesda, MD, USA)
(https://imagej.nih.gov/ij/) [74].
4.7. Cell Invasion Assay
The effects of TA on prostate cancer cell invasion were evaluated using BioCoat Matrigel Invasion
Chambers (BD Biosciences, Bedford, MA, USA) that were coated with basement membrane matrix.
Prostate cancer cells (3.5 × 104) were seeded in the upper chamber of the trans-well containing serum
free medium and cells treated with TA (10 and 20µM) for 24 h. The tumor cells in the upper chamber
were allowed to migrate into the lower chamber containing 20% FBS medium (750 µL). Cells in the top
well of the upper chamber were removed by wiping them off the top membrane with cotton swabs [75].
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The membranes were then fixed with 100% methanol and hematoxylin for 30 min for visualization of
cells. The percentage of invasion was calculated as mentioned in migration assay.
4.8. cDNA Synthesis and Quantitative mRNA Expression by Real-Time PCR
Total RNA isolation of untreated and treated prostate cancer cells was performed using an RNA
Isolation Kit (Qiagen Inc., Hilden, Germany). Quantity and quality of RNA were measured using
NanoDrop™ 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Reverse transcription of RNA
to cDNA was done using cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA). Then, cDNA was
stored at −20 ◦C for further use [71,72]. The effect of TA on mRNA expression in prostate cancer
cell lines was studied by quantitative Real Time PCR (qRT-PCR) using Roche Lightcycler 480 (Roche,
Basel, Switzerland), as described previously [75]. The primer sequences (forward and reverse primers)
of the genes are presented below (Table 1). Specific annealing temperatures were verified using
a gradient thermal cycler.
Table 1. Forward and reverse primer sequence of genes chosen in this study.









4.9. mRNA Purification, Ethanol Precipitation and Micro Array Studies
The mRNA was extracted from the TA treated C4-2 and PC-3 cells using RNA Isolation Kit
(Qiagen Inc., Hilden, Germany). The extracted RNA was further purified with slight modifications [76].
To the RNA, 3 times the volume of absolute ethanol, 10% of 3M sodium acetate and 2 µL of linear
acrylamide were added, mixed, vortexed, and left for incubation in−20 ◦C overnight. After incubation
the samples were centrifuged at 130,000× g for 10–15 min at 4 ◦C. The supernatant was discarded
without disturbing the pellet. 1 mL of 75–80% ethanol was added to the pellet and repeated this step.
The sample was subjected to quick spin, and the ethanol was carefully removed without disturbing
the pellet and it was allowed to dry, until the pellet turns opaque (avoid over drying). The pellet
was suspended in 40 µL of water and vortexed down. The resultant samples were subjected to
gene microarray studies using GeneChip® Human gene 2.0 ST array and SensationPlusTM FFPE
Amplification and WT Labeling Kit (Part# 902746) (Affymterix, Santa Clara, CA, USA).
4.10. Western Blot Analysis
The effects of TA on protein expression in prostate cancer cells were determined by Western blot
analyses. The process of extraction, quantification of proteins, and the Western blotting method were
followed, as previously described [67,77–79]. SDS-PAGE was performed on 4–20% gel and done using
Mini-PROTEAN Tetra Cell (Bio-Rad, Richmond, CA, USA) as described earlier [67]. Proteins were
transferred from gel to a nitrocellulose membrane using the trans-blot electrophoretic transfer cell
containing Tris-glycine buffer, pH 8.3, and methanol. The transfer was carried out at 0–4 ◦C for 150 min
at 55 V (400 mA) and blocked using 3% BSA for 1 h at Room temperature. Primary antibodies in 2% BSA
in PBST (Bip #3177, ATF4 #111815, IRE1α #3294, PDI #3501, CHOP #2895, PERK #5683, phospho-PERK
(Thr980) (16F8) #3179, Cyclin D1 #2978, p21Cip1/waf1 #2947, p18INK4C #2896, Bcl-xL #2764, Bcl-2 #2872,
Bak #3814, Bim #2819, Cleaved PARP #5625, Cleaved Caspase 3 #9664, E-cadherin #3195, MMP2 #4022,
MMP9 #3852, and β-Actin #4970) (Cell Signaling Technologies, Danvers, MA, USA) were probed
on a nitrocellulose membrane and were incubated at 4 ◦C overnight on rocker. After incubation,
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the blots were washed thrice with mean interval of 5 min; the membrane was further incubated
with HRP conjugated secondary antibodies for 45 min. Finally, the blots were washed with PBST
and bound to immunoreactive proteins on nitrocellulose membrane using Bio-Rad ECL Western
Blotting Substrate Solution (Bio-Rad Laboratories, Hercules, CA, USA). Gels were imaged using
a Bio-Rad computer-based gel imaging instrument and analyzed using ImageLabTM software (Bio-Rad
Laboratories, Hercules, CA, USA).
4.11. Statistical Analysis
Calculations and statistical analyses were carried out using GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA, USA). Mean ± SE of at least three sets of independent experiments were calculated
and analyzed via two-way repeated measure analysis of variance (ANOVA) and two-tailed student’s
t-test analysis. The level of significance was set to ** p < 0.01, *** p < 0.001.
5. Conclusions
Our data demonstrate the ability of TA to inhibit the growth of prostate cancer cells by arresting
cell cycle in G1 phase. Tannic acid induced ER stress-mediated UPR was examined, and the expression
of key indicators; Bip, IRE1α, and PDI were noted. The apoptotic potential of TA was determined.
The downregulation of pro-survival proteins (Bcl-2 and Bcl-xL), and upregulation of pro-apoptotic
markers (Bak, Bim, cleaved caspases 3) and cleaved poly (ADP-ribose) polymerase were revealed.
Additionally, our results deciphered the anti-metastic activity of TA and its intriguing role in inhibiting
EMT progression in prostate cancer cells. Overall, this study provides strong evidence that TA induces
ER stress mediated apoptosis and cell cycle arrest. Therefore, we believe that TA may offer a novel
natural monotherapy or a combination agent for prostate cancer.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/10/3/68/s1, Figure
S1. Real time gene expression studies ER stress markers in TA and Thapsigargin (TG) (Positive control for ER
stress) treated cells (PERK, EIF2S1, BiP, CHOP, and ATF4). The level of significance was represented as ** p < 0.01,
*** p < 0.001. Figure S2. Graphical representation of cells migrated/invaded after TA treatment in prostate cancer
cells. The level of significance was represented as ** p < 0.01, *** p < 0.001. Table S1. Various genes altered during
TA treatment (20 µM) in C4-2 and PC-3 prostate cancer cells.
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